CD19/BCMA CAR T-cells

BIOLOGICAL2 trials

Sponsors

Zhejiang University, Chengdu Ucello Biotechnology Co., Ltd.

Conditions

AmyloidosisAutoimmune Hemolytic AnemiaPOEMS SyndromeSLE - Systemic Lupus ErythematosusVasculitis

Early Phase 1

A Clinical Study of CD19/BCMA CAR-T Cells in the Treatment of Refractory POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia, and Vasculitis

Zhejiang UniversityAmyloidosis, Autoimmune Hemolytic Anemia, POEMS Syndrome +1

Start: 2021-10-08End: 2024-10-01Target: 75Updated: 2022-03-03

CD19/BCMA CAR-T for SLE

Not yet recruitingNCT07266337

Chengdu Ucello Biotechnology Co., Ltd.SLE - Systemic Lupus Erythematosus

Start: 2025-12-10End: 2037-12-31Target: 24Updated: 2025-12-05